On-Demand Presentations and Slides

Frequently Asked Questions in Locally Advanced SCCHN

Release date: 16-02-2022

Expiration date: 16-02-2023

The majority of patients with squamous cell head and neck cancer (SCCHN) present with locally advanced (LA) disease. The management of LA SCCHN is complex, and selecting the most appropriate treatment strategy for an individual patient requires a multidisciplinary team approach. Chemoradiation is the current gold standard for fit patients with LA SCCHN; however, despite treatment, many patients experience relapse. Research with new agents and combination strategies, which may provide additional benefits compared with chemoradiation, is promising. At the recent live webinar ’Frequently Asked Questions in LA SCCHN’, experts in the field discussed common questions in practice relating to the management of LA SCCHN and ongoing efforts to improve the outcomes of patients with LA disease. View expert presentations, panel discussions, and downloadable slides, and gain insights that may be helpful in your practice.

This program is available with subtitles in Chinese.

Faculty

Kunyu Yang, MD, PhD

Kunyu Yang, MD, PhD | Chair

Cancer Center, Union Hospital Tongji Medical College

Huazhong University of Science and Technology

Wuhan, China

Kunyu Yang is Professor and Chief of the Department of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. He received his Bachelor in Medicine from Wannan Medical College (Wuhu, 1994), his Master in Medicine from Tongij Medical Huazhong University of Science and Technology (Wuhan, 1997), and his doctoral degree from the Department of Radiation Oncology in Saarland University Hospital (Germany, 2004). Professor Yang is involved in clinical and translational research of head and neck cancer and received several research grants evaluating novel treatment modalities and radioresistance of nasopharyngeal cancer. He is author and co-author of many research articles published in peer reviewed journals.

Guopei Zhu, MD

Guopei Zhu, MD

The Shanghai Ninth People’s Hospital

Shanghai Jiaotong University School of Medicine

Shanghai, China

Guopei Zhu is the Chief Physician of Shanghai Ninth People’s Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China, and is the Director of Radiation Oncology Division in the Department of Oral and Maxillofacial-Head and Neck Oncology. Professor Zhu is Vice Chairman of the Head and Neck Cancer Professional Committee, and the Nasopharyngeal Carcinoma Professional Committee, of the Shanghai Anti-Cancer Association. Professor Zhu is a member of the Head and Neck Cancer Professional Committee of the Chinese Society of Clinical Oncology (CSCO), member of the Nasopharyngeal Carcinoma Professional Committee of CSCO and a member of the Standing Committee of the Oral and Maxillofacial Head and Neck Cancer Professional Committee of the Chinese Stomatological Association.

Jin-Ching Lin, MD, PhD

Jin-Ching Lin, MD, PhD

Changhua Christian Hospital

Changhua, Taiwan

Jin-Ching Lin is radiation oncologist at Changhua Christian Hospital and a part-time consultant at Taichung Veterans General Hospital, Taiwan where he served as a Director of Radiation Oncology (2004-2019). He has been a full professor at the National Yang-Ming University since 2007. Professor Lin won the outstanding research award from the National Science Council, Taiwan in 2004. He was leader of the educational training program for the Taiwan Society of Therapeutic Radiation Oncology (2008-2014) and Program Co-Director or Director of the Medical Engineering Division, Ministry of Science and Technology (2015- 2019). In 2018, Professor Lin was invited to be a member of the National Cancer Institute Head and Neck (H&N) Steering Committee on Clinical Trial Planning for Nasopharyngeal Cancer (NPC) in Bethesda, USA, and in 2020 he was invited to be a panel member for the CSCO-ASCO NPC Guidelines. His research interests focus on non-surgical treatments for all H&N cancers. Prof. Lin is internationally recognized as one of the pioneers in the field of circulating EBV DNA and NPC. He has published many articles in well recognized high impact journals 

Makoto Tahara, MD, PhD

Makoto Tahara, MD, PhD

National Cancer Center Hospital East

Kashiwa, Japan

Makoto Tahara is Chief of the Head and Neck Medical Oncology Department, National Cancer Center Hospital East (NCCHE), Kashiwa, Japan. He graduated in 1996 from Hiroshima University School of Medicine, Japan, did his internal medicine training at Hiroshima University Hospital of Medicine, and became a board-certified specialist in Internal Medicine in 2003. Dr. Tahara has worked in the field of Medical Oncology since 1998, initially as a resident in NCCHE, and later as a staff physician in the Division of Oncology/ Hematology at the same institute; he became a board-certified specialist in Medical Oncology in 2006 and received his PhD in Medical Sciences in 2004 from Hiroshima University School of Medicine. Dr. Tahara was a Visiting Associate Professor within the department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Texas, US, from 2007 to 2008, and this became his current position in 2012; he has been a Visting Professor at Tokai University School of Medicine,Tokyo, Japan, since 2014. Dr. Tahara is interested in developing a novel head and neck cancer treatment, including thyroid cancer, and has been a principal investigator on eight investigator-initiated clinical studies. He has been a steering committee member in 15 global clinical studies. In addition, he was a group manager of the Head and Neck Cancer Group in the Japanese Clinical Oncology Group (JCOG) from 2012 to 2016. Dr. Tahara has served as a reviewer or member of the editorial board of five international journals and has authored more than 150 international scientific papers. He received an award from the alumni association of the National Cancer Center in 2005 and a “Paper of the year 2005” award in the Japanese Journal of Clinical Oncology.

Yungan Tao, MD, PhD

Yungan Tao, MD, PhD

Gustave Roussy

Villejuif, France

Yungan Tao is Chief Radiation Oncologist of head and neck / dermatology / endocrinology in the Department of Radiation Oncology at Institut Gustave-Roussy, Villejuif, France. Dr. Tao is Principal Investigator (PI) or co-PI of several international / European and French national clinical phase II/III studies, utilizing new radiotherapy technology, and investigating the association of targeted therapy or immunotherapy with chemoradiotherapy, for example. He is also interested in translational research, particularly regarding the radiosensitivity of head and neck cancer related to new targeted therapy and immuno-biomarkers. Dr. Tao’s recent publications as first/co-first/last author include JCO, Lancet Oncol, and Nature Reviews Clinical Oncology.

Dr. Tao is Vice-President and member of the executive committee and scientific committee of the French head and neck oncology radiotherapy group (GORTEC). He is also a member of the Scientific Committee of French Head and Neck Intergroup and a Radiation Oncology Expert in Unicancer Head and Neck Group. He is the key investigator/radiation oncologist in the Head and Neck Group of European Organisation for Research and Treatment of Cancer (EORTC) and Expert Panelist for the nasopharyngeal cancer project in the International Atomic Energy Agency (IAEA). Dr. Tao is also a board member at Head and Neck Cancer International Group (HNCIG).

  • Managing LA SCCHN in 2021: Do you know the latest guidelines? | Guopei Zhu, MD

FREQUENTLY ASKED QUESTIONS

 

  • Q1: Which patients are cisplatin ineligible, and how should I treat them? | Jin-Ching Lin, MD, PhD

  • Q2: Is there a role for immunotherapy in LA SCCHN? | Kunyu Yang, MD, PhD

  • Panel discussion 1, and questions from the audience | Moderated by Makoto Tahara, MD, PhD

  • Q3: How can we enhance efficacy of chemoradiation in HPV-negative LA SCCHN? | Yungan Tao MD, PhD

  • Q4: When, how, and for whom can we use induction therapy in LA SCCHN? | Guopei Zhu, MD

  • Q5: How can we treat local progression after primary treatment of LA SCCHN? | Makoto Tahara, MD, PhD

  • Panel discussion 2, and questions from the audience | Moderated by Kunyu Yang, MD, PhD

This program is designed specifically for radiation oncologists, medical oncologists, and other members of the head and neck multidisciplinary team involved in the treatment of patients with head and neck cancer.

Upon completion of this educational activity, participants should be able to:

 

  • Evaluate current treatment options for patients with LA SCCHN (HPV+ and HPV-)
  • Identify patients with LA SCCHN who are unfit for cisplatin-based therapy, and select alternative treatment options
  • Explain strategies that may enhance chemoradiation efficacy in high-risk LA SCCHN, and describe the role of immunotherapy and induction chemotherapy in this setting
  • Assess treatment options for patients with local progression after definitive chemoradiation

This educational activity is provided by ACE Oncology.

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

 

Kunyu Yang has served as an advisor or consultant for Merck KGaA. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Guopei Zhu has received grants for clinical research from Jiangsu Hengrui Medicine Co., Ltd, Clinical Research Program of 9th People’s Hospital, and the Shanghai Jiao Tong University School of Medicine. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Jin-Ching Lin has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Makoto Tahara has served as an advisor or consultant for Merck Biopharma, MSD, BMS, Ono Pharmaceutical, Eisai, Lilly, Loxo Oncology Celgene, Amgen, and Rakuten Medical. Dr. Tahara has also received grants for clinical research from Bayer and Ono Pharmaceutical. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Yungan Tao has served as an advisor or consultant for Ipsen, MSD, and Merck. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

The employees of ACE Oncology have disclosed no relevant financial relationships.

 

ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Start Activity